Journal of International Psychiatry

[Abstract] Objective: To explore the value of combination of tiapride and levetiracetam in controlling the condition of Tourettes disease. Methods: Following the principle of randomization, 50 patients with Tourettes disease diagnosed in our hospital from April 2020 to April 2022 were selected and divided into two groups. The control group (odd number) was treated with Tiapride. The observation group (odd number) was treated with levetiracetam on the basis of the control group, with 25 patients in each group. Evaluate the clinical treatment effect, record the incidence of adverse reactions after treatment, and analyze the clinical indicators and mental state of the two groups. Results: The clinical efficacy of the observation group was 96.00%, higher than that of the control group (76.00%, P<0.05); There was no difference in the incidence of adverse reactions between the observation group (20.00%) and the control group (16.00%) (P>0.05); The scores of motor tic and vocal tic in the observation group were lower than those in the control group (P<0.05); The twitch frequency, twitch frequency and twitch intensity in the observation group were lower than those in the control group (P<0.05); The score of self-consciousness in the observation group was higher than that in the control group, and the score of anxiety and depression was lower than that in the control group (P<0.05). Conclusion: In the treatment of Tourettes disease in children, the combination of tiapride and levetiracetam can significantly improve their mental state, alleviate their condition and ensure the safety and effectiveness of treatment.

Key words: Thiopride; Levetiracetam; children; Tourette syndrome; Adverse reactions